Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Edit functionality is currently unavailable.

Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.

Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA, Chyla B, Zhou L, Agarwal S, Waskiewicz T, Verdugo M, Humerickhouse RA, Potluri J, Wierda WG, Davids MS. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018 04 12; 131(15):1704-1711.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.